Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06881836 · ClinicalTrials.gov registry record · Phase 2
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by Ono Pharmaceutical Co..
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06881836: Active Phase 2 study of Alzheimer Disease, sponsored by Ono Pharmaceutical Co..
NCT06881836 is a Phase 2 study of Alzheimer Disease that is active but no longer recruiting, run by Ono Pharmaceutical Co.. The registered enrollment target is 240 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06881836, a Phase 2 study of Alzheimer Disease, is active but no longer recruiting, sponsored by Ono Pharmaceutical Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.
Primary Outcome
The number and percentage of subjects reporting each TEAE will be summarized by both system organ class (SOC) and preferred term (PT).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ONO-2020
Study Locations (20)
Florida
- Brain Matters Research - Delray Beach
- Velocity Clinical Research, Hallandale Beach - Hallandale
- Premier Clinical Research Institute; Inc. - Miami
- Quantum Clinical Trials - Miami Beach
- Suncoast Clinical Research - New Port Richey
- Renstar Medical Research - Ocala
- Charter Research - Orlando - Orlando
- Accel Research Sites - Brain and Spine Institute - Port Orange
- USF Health Byrd Alzheimer's Institute - Tampa
- ForCare Clinical Research - Tampa
Arizona
- Banner Alzheimer's Institute (BAI) - Phoenix
- Clinical Endpoints - Scottsdale
- Banner Sun Health Research Institute - Sun City
- Center for Neurosciences-Research - Tucson
California
- Profound Research LLC at The Neurology Center of Southern California - Carlsbad
- Neurology Center of North Orange County - Fullerton
- Stanford University - Palo Alto
- Sunwise Clinical Research - Walnut Creek
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- CenExel Rocky Mountain Clinical Research - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-04-24 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What the registry record for NCT06881836 still lists
NCT06881836 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06881836 names 20 study sites across 5 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06881836 about?
NCT06881836 is a clinical study titled "A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease". This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, m...
What is the current status of trial NCT06881836?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-04-24. Estimated completion is 2026-08.
What conditions does trial NCT06881836 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06881836?
The interventions under investigation include: Placebo (DRUG), ONO-2020 (DRUG).
Who is sponsoring clinical trial NCT06881836?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06881836 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06881836's enrollment target sits among peer trials
240 94th of 306 higher than 209 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI